456 related articles for article (PubMed ID: 32511029)
21. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.
Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM
Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013
[TBL] [Abstract][Full Text] [Related]
22. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism.
Xie B; Qiu Y; Zhou J; Du D; Ma H; Ji J; Zhu L; Zhang W
Clin Transl Oncol; 2022 Nov; 24(11):2231-2240. PubMed ID: 35852680
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse.
Dagogo-Jack I; Oxnard GR; Evangelist M; Digumarthy SR; Lin JJ; Gainor JF; Murphy JF; Rabin MS; Heist RS; Muzikansky A; Shaw AT
JCO Precis Oncol; 2022 May; 6():e2100522. PubMed ID: 35584349
[TBL] [Abstract][Full Text] [Related]
24. Lorlatinib as a treatment for ALK-positive lung cancer.
Baba K; Goto Y
Future Oncol; 2022 Aug; 18(24):2745-2766. PubMed ID: 35787143
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
Luo X; Zhou Z; Zeng X; Peng L; Liu Q
Front Public Health; 2022; 10():985834. PubMed ID: 36211665
[TBL] [Abstract][Full Text] [Related]
26. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
Zhao M; Shao T; Shao H; Zhou C; Tang W
BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
[TBL] [Abstract][Full Text] [Related]
27. Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients.
Lee PH; Chen KC; Hsu KH; Huang YH; Tseng JS; Yang TY; Chang GC
Anticancer Drugs; 2021 Nov; 32(10):1099-1104. PubMed ID: 34232936
[TBL] [Abstract][Full Text] [Related]
28. An update on lorlatinib: a novel first line treatment for
Riudavets M; Planchard D
Expert Opin Pharmacother; 2023 Feb; 24(3):291-299. PubMed ID: 36542835
[TBL] [Abstract][Full Text] [Related]
29. Canadian perspectives: update on inhibition of
Melosky B; Cheema P; Agulnik J; Albadine R; Bebb DG; Blais N; Burkes R; Butts C; Card PB; Chan AMY; Hirsh V; Ionescu DN; Juergens R; Morzycki W; Poonja Z; Sangha R; Tehfe M; Tsao MS; Vincent M; Xu Z; Liu G
Curr Oncol; 2018 Oct; 25(5):317-328. PubMed ID: 30464681
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.
Lee J; Sun JM; Lee SH; Ahn JS; Park K; Choi Y; Ahn MJ
Clin Lung Cancer; 2019 May; 20(3):215-221. PubMed ID: 30683630
[TBL] [Abstract][Full Text] [Related]
31. Response to lorlatinib on a patient with ALK-rearranged non-small cell lung cancer harboring 1151Tins mutation with uterine metastasis.
Kobayashi T; Kanda S; Fukushima T; Noguchi T; Sekiguchi N; Koizumi T
Thorac Cancer; 2021 Aug; 12(16):2275-2278. PubMed ID: 34184417
[TBL] [Abstract][Full Text] [Related]
32. Pan-HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK-rearranged lung cancer.
Taniguchi H; Akagi K; Dotsu Y; Yamada T; Ono S; Imamura E; Gyotoku H; Takemoto S; Yamaguchi H; Sen T; Yano S; Mukae H
Cancer Sci; 2023 Jan; 114(1):164-173. PubMed ID: 36086904
[TBL] [Abstract][Full Text] [Related]
33. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapeutic advances with anaplastic lymphoma kinase inhibitors for the treatment of non-small cell lung cancer.
Indini A; Rijavec E; Ghidini M; Bareggi C; Gambini D; Galassi B; Antonelli P; Bettio G; Di Nubila C; Grossi F
Expert Opin Pharmacother; 2020 Jun; 21(8):931-940. PubMed ID: 32162559
[TBL] [Abstract][Full Text] [Related]
35. From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.
Ou SI; Lee ATM; Nagasaka M
Crit Rev Oncol Hematol; 2023 Jul; 187():104019. PubMed ID: 37187318
[TBL] [Abstract][Full Text] [Related]
36. Lorlatinib as a first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: Α cost-effectiveness analysis in Greece.
Gourzoulidis G; Zisimopoulou O; Liavas A; Tzanetakos C
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):375-385. PubMed ID: 37997764
[TBL] [Abstract][Full Text] [Related]
37. Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G; Mezquita L; Facchinetti F; Planchard D; Gazzah A; Bigot L; Rizvi AZ; Frias RL; Thiery JP; Scoazec JY; Sourisseau T; Howarth K; Deas O; Samofalova D; Galissant J; Tesson P; Braye F; Naltet C; Lavaud P; Mahjoubi L; Abou Lovergne A; Vassal G; Bahleda R; Hollebecque A; Nicotra C; Ngo-Camus M; Michiels S; Lacroix L; Richon C; Auger N; De Baere T; Tselikas L; Solary E; Angevin E; Eggermont AM; Andre F; Massard C; Olaussen KA; Soria JC; Besse B; Friboulet L
Clin Cancer Res; 2020 Jan; 26(1):242-255. PubMed ID: 31585938
[TBL] [Abstract][Full Text] [Related]
38. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice.
Caccese M; Ferrara R; Pilotto S; Carbognin L; Grizzi G; Caliò A; Brunelli M; Cuppone F; Petraglia S; Scarpa A; Tortora G; Bria E
Expert Opin Pharmacother; 2016 Dec; 17(17):2253-2266. PubMed ID: 27682212
[TBL] [Abstract][Full Text] [Related]
39. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
Nishio M; Murakami H; Horiike A; Takahashi T; Hirai F; Suenaga N; Tajima T; Tokushige K; Ishii M; Boral A; Robson M; Seto T
J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
Sun S; Pithavala YK; Martini JF; Chen J
J Clin Pharmacol; 2022 Sep; 62(9):1170-1176. PubMed ID: 35373356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]